Sign in
Taking peoplePhase 2

Tildrakizumab for chronic spontaneous urticaria that has not responded to treatment

Tests tildrakizumab in adults with hard-to-treat chronic spontaneous urticaria, tracking hive symptoms.

Key facts

Who runs it
Philipps-Universitaet Marburg
Where
Germany1 site in 1 countryChoose a country to see its sites
Registry title
Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)
Status
Recruiting
Phase
Phase 2
People taking part
18 people, planned
Started
2 Mar 2026
Expected to end
30 Sept 2028
Type of study
Interventional
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic spontaneous urticaria (hives with no clear trigger) that continues despite antihistamine treatment. It tests tildrakizumab.

Age
18 years and older
Sex
All sexes
Disease stage
Chronic spontaneous urticaria for at least 6 weeks, with hives and itching for at least 6 weeks despite H1 antihistamine treatment. Urticaria activity score UAS7 (range 0–42) of 16 or more.
Earlier treatment
People must be taking H1 antihistamines (H1 blockers) at a stable dose. People cannot join if they had immune-suppressing or immune-changing treatment. For omalizumab, the last dose must be at least 3 months before the start.
Biomarker or test result
An IL-17-mediated T-cell immune profile, shown by a blood test called flow cytometry.

Main reasons for not taking part

  • Hives mainly triggered by things like cold or pressure
  • Current autoimmune disease, such as rheumatoid arthritis, lupus or multiple sclerosis
  • Past cancer, except treated non-melanoma skin cancer
  • Active or latent tuberculosis, or another active widespread skin disease like psoriasis or atopic eczema
  • Pregnancy, breastfeeding, or a live vaccine within 1 month before the study or planned

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • CSU for ≥ 6 weeks, hives and itching for ≥ 6 weeks despite H1 antihistamine treatment at screening
  • Must be on stable co-medication with H1 blockers
  • IL-17-mediated T-cellular immune profile as determined by flow cytometry
  • UAS7 (range 0–42) of ≥ 16
  • Signed written informed consent
  • For women of childbearing potential (WOCBP): A negative result in highly sensitive pregnancy test and willingness of additional pregnancy testing monthly up to the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Tildrakizumab is achieved after 17 weeks after the last administration of Tildrakizumab
  • Willingness of women of childbearing potential (WOCBP) to use highly effective methods of contraception* during treatment and until the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Tildrakizumab is achieved after 17 weeks after the last administration of Tildrakizumab

Who cannot take part

  • Immunization with live vaccines (planned or within 1 month prior to the study)
  • Current/active autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematodes, multiple sclerosis etc
  • History of malignancy (with the exception of adequately treated non-melanoma skin cancer)
  • Active or latent tuberculosis
  • Any active generalized skin disease like psoriasis or atopic eczema
  • Primarily subtype of inducible chronic urticaria (e.g. cold, pressure)
  • Participation in other clinical trials
  • Immunosuppressive or -modulatory treatments, including omalizumab, the latter for less than 3 half-lives (that means 3 months) before starting treatment at baseline
  • Pregnant women
  • Breast-feeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the change in UAS (Urticaria Activity Score) 7 from baseline to week 20.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)
Plain-language title
Tildrakizumab for chronic spontaneous urticaria that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
2 November 2026